PMID- 32770441
OWN - NLM
STAT- MEDLINE
DCOM- 20211021
LR  - 20211021
IS  - 1776-260X (Electronic)
IS  - 1776-2596 (Print)
IS  - 1776-2596 (Linking)
VI  - 15
IP  - 4
DP  - 2020 Aug
TI  - Management of Adverse Events Associated with Cabozantinib Treatment in Patients 
      with Advanced Hepatocellular Carcinoma.
PG  - 549-565
LID - 10.1007/s11523-020-00736-8 [doi]
AB  - Cabozantinib is an oral multikinase inhibitor whose targets include vascular 
      endothelial growth factor receptors, MET, and the TAM family of kinases (TYRO3, 
      AXL, MER). Cabozantinib is approved for patients with advanced hepatocellular 
      carcinoma who have been previously treated with sorafenib, based on improved 
      overall survival and progression-free survival relative to placebo in the phase 
      III CELESTIAL study. During CELESTIAL, the most common adverse events (AEs) 
      experienced by patients receiving cabozantinib included palmar-plantar 
      erythrodysesthesia, fatigue, gastrointestinal-related events, and hypertension. 
      These AEs can significantly impact treatment tolerability and patient quality of 
      life. However, AEs can be effectively managed with supportive care and dose 
      modifications. During CELESTIAL, more than half of the patients receiving 
      cabozantinib required a dose reduction, while the rate of treatment 
      discontinuation due to AEs was low. Here, we review the safety profile of 
      cabozantinib and provide guidance on the prevention and management of the more 
      common AEs, based on current evidence from the literature as well as our clinical 
      experience. We consider the specific challenges faced by clinicians in treating 
      this patient population and discuss factors that may affect exposure and 
      tolerability to cabozantinib.
FAU - Schwartz, Gabriel
AU  - Schwartz G
AD  - Gastrointestinal Medical Oncology Clinic, University of California San Francisco, 
      1825 Fourth St, Fourth Floor, San Francisco, CA, 94158, USA. 
      Gabriel.Schwartz@ucsf.edu.
FAU - Darling, Julianne O
AU  - Darling JO
AD  - Indiana University Health Simon Cancer Center, Indianapolis, IN, USA.
FAU - Mindo, Malori
AU  - Mindo M
AD  - Department of Medicine, University of California San Francisco, San Francisco, 
      CA, USA.
FAU - Damicis, Lucia
AU  - Damicis L
AD  - IRCCS Istituto Clinico Humanitas, Rozzano, Milan, Italy.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - France
TA  - Target Oncol
JT  - Targeted oncology
JID - 101270595
RN  - 0 (Anilides)
RN  - 0 (Pyridines)
RN  - 1C39JW444G (cabozantinib)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
SB  - IM
MH  - Anilides/*adverse effects/pharmacology
MH  - Carcinoma, Hepatocellular/*complications/*drug therapy
MH  - Female
MH  - Humans
MH  - Liver Neoplasms/*complications/*drug therapy
MH  - Male
MH  - Pyridines/*adverse effects/pharmacology
MH  - Quality of Life
MH  - Receptor Protein-Tyrosine Kinases/*adverse effects/pharmacology
PMC - PMC7434721
COIS- GS reports advisory board or speaker bureau fees from Exelixis, Eisai, and Amgen 
      (all outside of the submitted work); JOD reports advisory board fees from 
      Exelixis, Bayer, and Lilly (all outside of the submitted work); MM and LD have 
      nothing to disclose.
EDAT- 2020/08/10 06:00
MHDA- 2023/02/25 06:00
PMCR- 2020/08/08
CRDT- 2020/08/10 06:00
PHST- 2020/08/10 06:00 [pubmed]
PHST- 2023/02/25 06:00 [medline]
PHST- 2020/08/10 06:00 [entrez]
PHST- 2020/08/08 00:00 [pmc-release]
AID - 10.1007/s11523-020-00736-8 [pii]
AID - 736 [pii]
AID - 10.1007/s11523-020-00736-8 [doi]
PST - ppublish
SO  - Target Oncol. 2020 Aug;15(4):549-565. doi: 10.1007/s11523-020-00736-8.